A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma


Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content